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To investigate the role of serine/threonine autophos-
phorylation of protein kinase C-d (PKC-d), we mutated
serine 643 of PKC-d to an alanine residue (PKC-dS643A).
Two different expression vectors containing PKC-
dS643A mutant cDNAs were transfected and expressed
in 32D myeloid progenitor cells. In vitro autophospho-
rylation assays demonstrated 65–83% reduction in auto-
phosphorylation of PKC-dS643A in comparison to wild
type PKC-d (PKC-dWT). The enzymatic activity of PKC-
dS643A mutant as measured by phosphorylating the
PKC-d pseudosubstrate region-derived substrate was
also reduced more than 70% in comparison to that of
PKC-dWT. In vivo labeling and subsequent two-dimen-
sional phosphopeptide analysis demonstrated that at
least one phosphopeptide was absent in PKC-dS643A
when compared with PKC-dWT, further substantiating
that serine 643 is phosphorylated in vivo. Localization
and 12-O-tetradecanoylphorbol-13-acetate-dependent
translocation and tyrosine phosphorylation of PKC-
dS643A were not altered in comparison to PKC-dWT,
indicating that mutagenesis did not affect the structural
integrity of the mutant protein. 12-O-Tetradecanoyl-
phorbol-13-acetate-mediated monocytic differentiation
of 32D cells overexpressing PKC-dS643A mutant protein
was impaired in comparison to that of PKC-dWT trans-
fectant. Taken together, our results demonstrate that
serine 643 of PKC-d is a major autophosphorylation site,
and phosphorylation of this site plays an important role
in controlling its enzymatic activity and biological
function.
Protein kinase C (PKC)1 is composed of a family of serine/
threonine kinases. To date, 11 different PKC isoenzymes have
been identified that are divided into three different subgroups,
conventional PKCs (cPKCs), novel PKCs (nPKCs), and atypical
PKCs (1–3). PKCs have been defined as important signaling
molecules in cell growth, differentiation, secretion of hormones
and neurotransmitters, and cellular transformation (2). PKC-d
belongs to nPKC subgroup and is ubiquitously expressed in
many tissues and cell lines (4).
We have focused our efforts on understanding the role of
PKC-d in various signaling transduction pathways. Overex-
pression of wild type of PKC-d (PKC-dWT) in 32D myeloid
progenitor cells led to monocytic differentiation in response to
12-O-tetradecanoylphorbol-13-acetate (TPA) treatment (5),
suggesting a causal role for PKC-d in hematopoietic cell differ-
entiation. An ATP binding mutant of PKC-d (PKC-dK376R)
was generated by site-directed mutagenesis and was demon-
strated to lack autophosphorylation capacity in vitro com-
pletely (6). Moreover, the PKC-dK376R mutant competitively
inhibited PKC-dWT phosphorylation of an exogenous substrate
in vitro. Recently, our group and several others (7–12) observed
tyrosine phosphorylation of PKC-d in vivo in response to its
activation by various agonists. PKC-d was also demonstrated to
be an important substrate in the platelet-derived growth factor
b receptor (PDGF-bR) pathway (13). It was phosphorylated by
the activated PDGF-bR in vivo and in vitro on tyrosine resi-
due(s) (10, 13). The relevance of PKC-d in mediating c-sis/
PDGF-B transformation of NIH 3T3 cells was recently eluci-
dated (14). In this study, expression of the PKC-dK376R
mutant led to dramatic inhibition of c-sis-induced NIH 3T3 cell
transformation. These results demonstrate that PKC-d plays a
physiological role in a signaling pathway leading to malignant
transformation of fibroblasts induced by sis oncogene.
Serine/threonine phosphorylation of PKC in vivo was first
observed approximately 10 years ago (15–19). Several in vivo
phosphorylation sites have been mapped utilizing different
methods (20–22). Based on studies performed on cPKCs (20,
23–27), it is generally believed that PKC is first synthesized as
an immature precursor protein that does not show any cata-
lytic activity. Phosphorylation of PKC on the “activation loop,”
which corresponds to threonines 497 and 500 of PKC-a (23) and
bII (26), respectively, by an unidentified PKC kinase then
renders PKC catalytic domain competent. However, transphos-
phorylation of PKC on its activation loop does not alter the
mobility of the protein as observed by SDS-polyacrylamide gel
electrophoresis (PAGE). Subsequent autophosphorylation on
threonine 641 of PKC-bII results in the first upward shift of the
mobility of the protein. This event is followed by a second
autophosphorylation on serine 660 of PKC-bII which further
shifts the protein to the mature 80-kDa form. Generation of
diacylglycerol through different mechanisms recruits PKC to
the membrane where the pseudosubstrate region-mediated au-
toinhibition of the catalytic domain is released. The enzyme is
then able to phosphorylate substrates and transmit the down-
stream signals. How the mature enzyme returns to the cytosol
after activation remains unclear. This may be regulated by
serine/threonine phosphatase activity (1).
Autophosphorylation of PKC has been observed both in vivo
and in vitro (15–19). It is thought that autophosphorylation of
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PKC enhances its binding to phorbol ester and reduces the Km
for its substrates in vitro (16, 18). Several in vivo autophospho-
rylation sites for different PKC isoenzymes have been mapped
(20–22). Recently, conserved threonine autophosphorylation
sites on two cPKCs (PKC-a and PKC-bI) were characterized by
site-directed mutagenesis (23, 28, 29). Mutation of threonine
638 to alanine in the PKC-a molecule did not dramatically
affect its enzymatic activity (23). In striking contrast, mutation
of this conserved site (threonine 642 to alanine) in PKC-bI
completely abolished its enzymatic activity and in vivo phos-
phorylation (29). Since PKC-d belongs to the nPKC subfamily
and a serine residue rather than a threonine residue exists at
this conserved position (see Fig. 1), we have attempted to
elucidate whether PKC-d is phosphorylated on this conserved
site and, if so, whether this phosphorylation would influence
PKC-d function. Our results indicate that serine 643 is a major
PKC-d autophosphorylation site, and phosphorylation of this
site significantly affects its enzymatic activity.
EXPERIMENTAL PROCEDURES
Construction of a Serine to Alanine Mutant of Murine PKC-d, cDNA
Expression Vectors, and Cell Lines—The Bio-Rad Muta-gene Phagemid
in vitro mutagenesis kit (version 2) was used for the site-directed
mutagenesis. The oligonucleotide 59-GAATGAGAAACCTCAGCTTG-
CATTCAG-39 was used as a mutant primer in the in vitro mutagenesis
reaction where the serine residue at amino acid 643 of murine PKC-d
was changed to alanine (underlined in the sequence). The successful
mutation of this site generated a new BsmI restriction site that was
used to screen all the reaction products. The mutation was confirmed by
DNA sequencing. The PKC-dS643A mutant cDNA was subcloned into
pCEV-HA (three hemagglutinin epitope repeats, neo selection) and
pLTR (two HA epitope repeats, gpt selection) vectors, generating pCEV-
dS643A-HA and pLTR-dS643A-HA, respectively. The generation of
these two vectors and subcloning of PKC-dWT cDNA into these vectors
have been previously described (6, 30). The 32D cells were transfected
with different cDNA expression vectors using the electroporation pro-
cedure described previously (5). 32D cells and transfectants were cul-
tured in RPMI 1640 medium with 10% fetal calf serum and 5%
WEHI-3B conditioned medium as a source of murine interleukin-3.
Immunoprecipitation, Immunoblot Analysis, and Subcellular Frac-
tionation—These procedures have been described previously (6, 10, 13,
30). Briefly, the 32D transfectants were serum-starved for 2 h and left
untreated or stimulated with 100 ng/ml TPA (Sigma) for 10 min. The
cell pellets were lysed in Triton X-100 containing lysis buffer (13) and
clarified by centrifugation. For immunoprecipitation, equal amounts of
proteins (1–5 mg per sample) were incubated with polyclonal anti-
PKC-d serum (5 ml per sample, Calbiochem) together with 40 ml of
protein G-coupled Sepharose (Pharmacia Biotech, Inc.) or with anti-HA
monoclonal antibody (mAb; 4 mg per sample, Boehringer Mannheim)
together with 25 ml of protein A-Sepharose beads (Pierce). Anti-phos-
photyrosine (anti-Tyr(P), 2 mg/ml, Upstate Biotechnology) and anti-
PKC-d (1:1000) were utilized for immunoblot analysis. The enhanced
chemiluminescence system (Amersham Corp.) was used to visualize
proteins, and the densities of the bands from SDS-PAGE and autora-
diography were quantified by using a densitometer (Molecular Dynam-
ics). The method for the subcellular fractionation has been described
before (6, 13).
In Vitro PKC-d Autophosphorylation Assay—The in vitro autophos-
phorylation assay utilizing anti-HA antibody for immunoprecipitation
was performed by following a previously described protocol (6). Briefly,
cell lysates were immunoprecipitated with anti-HA antibody as de-
scribed above. Washed immunoprecipitates were incubated on ice for 30
min with 50 ml of autophosphorylation buffer that contained 20 mM
Tris-HCl, pH 7.5, 5 mM magnesium acetate, 50 mg/ml phosphatidyl-
serine (Sigma), 100 ng/ml TPA, 10 mg/ml leupeptin, 1 mM Na3VO4, 1 mM
ATP (Boehringer Mannheim), and 5 mCi of [g-32P]ATP (3000 Ci/mmol,
Amersham Corp.). The reaction was stopped by washing twice with
Triton X-100 containing lysis buffer, and denatured proteins were sep-
arated by SDS-PAGE. The dried gel was autoradiographed.
In Vivo Labeling and Two-dimensional Phosphopeptide Analysis—
Both in vivo labeling and subsequent two-dimensional phosphopeptide
analysis have been described previously (30). Briefly, serum-starved
32D transfectants were labeled with [32P]orthophosphate (1 mCi/ml;
NEN Life Science Products) for 3 h and were stimulated with TPA (100
ng/ml) for 10 min. Cell lysates were immunoprecipitated with anti-HA
mAb, and immunoprecipitates were resolved by SDS-PAGE. Radiola-
beled PKC-dWT-HA and PKC-dS643A-HA bands were excised from the
gel and exhaustively digested with trypsin (tosylphenylalanyl chloro-
methyl ketone-treated). The resulting phosphopeptides were resolved
by thin layer electrophoresis, pH 8.9, followed by ascending chromatog-
raphy, pH 1.9. Dried plates were autoradiographed for 1 week.
In Vitro PKC-d Activity Assays—DE52 ion exchange chromatography
to enrich PKC from the cell lysates and the subsequent measurement of
PKC activity utilizing PKC-d pseudosubstrate region-derived peptide as
a substrate have been described previously (6, 13, 30). Direct measure-
ment of PKC-d activity on PKC-d substrate utilizing anti-HA immuno-
precipitates as the kinase sources was also employed. Briefly, the equal
amounts of protein (6 mg per sample) from the various PKC-d trans-
fectants were immunoprecipitated with anti-HA antibody (4 mg per
sample). Washed immunoprecipitates were incubated at room temper-
ature with 40 ml of reaction buffer that contained 10 mM PKC-d sub-
strate derived from PKC-d pseudosubstrate region (6), 20 mM Tris-HCl,
pH 7.5, 1 mM CaCl2, 10 mM magnesium acetate, 1 mM TPA, 50 mg/ml
phosphatidylserine (Sigma), 30 mM ATP, and 30 mCi of [g-32P]ATP for
20 min. The reaction tube was centrifuged, and 20 ml of the supernatant
was spotted on phosphocellulase disk sheets (Life Technologies, Inc.).
The sheets were washed twice with 1% phosphoric acid and twice with
distilled water, and samples were analyzed by liquid scintillation. The
nonspecific catalytic activity was measured in the same reaction buffer
except that TPA and phosphatidylserine were omitted from the reac-
tion. The specific PKC-d activity was calculated by subtracting the
nonspecific catalytic activity from the total catalytic activity and ex-
pressed as counts per min (cpm).
Flow Cytometry—32D cells or 32D transfectants were untreated or
exposed to TPA (100 ng/ml) overnight. Cells were incubated with fluo-
rescein isothiocyanate-conjugated anti-Mac-1 (CalTag) or anti-FcgII/III
receptor (anti-FcgII/IIIR, Pharmigen) as described previously (6, 30).
The cells were subjected to flow cytometry using a Becton-Dickinson
FACScan.
FIG. 1. Serine 643 of PKC-d is a conserved phosphorylation site
in other PKC isoenzymes. Sequence alignment is based on the pre-
vious report described by Keranen et al. (20). In vivo phosphorylation of
PKC-a, -bI, and -bII at the threonine sites 638, 642, and 641, respec-
tively, has been demonstrated (20, 23, 29). These sites correspond to
serine 643 in PKC-d. The conserved residues are shown as bold letters.
FIG. 2. The PKC-dS643A mutant protein is expressed in the
various 32D transfectants. Equal amounts of cell lysates (4 mg per
sample) from 32D cells and transfectants were immunoprecipitated (IP)
with anti-PKC-d serum. Washed immunoprecipitates were subjected to
SDS-PAGE, and proteins transferred to an Immobilon membrane were
immunoblotted (Blot) with anti-HA mAb.
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RESULTS
Mutation of PKC-d Serine 643 and Expression of This Mutant
in 32D Cells—In an attempt to define which amino acids within
PKC-d are autophosphorylation sites and determine whether
mutation of one of these sites would affect PKC-d enzymatic
activity, we chose to mutate serine 643 to alanine by site-
directed mutagenesis. This putative autophosphorylation site
is conserved in other PKC sequences, including PKC-a, PKC-
bI, and PKC-bII (Fig. 1). In vivo phosphopeptide mapping or
site-directed mutagenesis of the corresponding threonine sites
within PKC-a, PKC-bI, and PKC-bII revealed that these resi-
dues were all phosphorylated in vivo (20–23, 28, 29). The
mutant cDNA, designated PKC-dS643A, was inserted into the
pCEV-HA (3 3 HA repeats) vector, generating pCEV-dS643A-
HA, or into pLTR-HA vector (2 3 HA repeats), generating
pLTR-dS643A-HA. PKC-dWT cDNA was previously inserted
into these same vectors and designated pCEV-dWT-HA and
pLTR-dWT-HA, respectively (30).
32D cells were transfected with expression vectors contain-
ing the various cDNA constructs, and drug-resistant 32D
transfectants were subjected to immunoprecipitation and im-
munoblot analysis to detect PKC-dS643A and PKC-dWT ex-
pression. As shown in Fig. 2, immunoprecipitation with anti-
PKC-d serum followed by immunoblot analysis with the
anti-HA mAb detected both pLTR-dWT-HA and pCEV-
dWT-HA proteins with mobilities of 80 and 90 kDa, respec-
tively. The mobilities of PKC-dWT proteins expressed in these
two vectors were identical to those reported in our previous
study (30). Endogenous PKC-d expression in 32D cells was not
detected, since the anti-HA mAb was utilized for immunopre-
cipitation. The levels of PKC-dS643A expression in cells trans-
fected with pLTR-HA and pCEV-HA vectors were 2.8- and
1.8-fold higher than those of PKC-dWT in the corresponding
vectors, respectively (Fig. 2).
Autophosphorylation of the PKC-dS643A Mutant Is Reduced
in Comparison to That of PKC-dWT—We performed in vitro
autophosphorylation assays utilizing the anti-HA mAb for im-
munoprecipitation. As shown in Fig. 3A, autophosphorylation
of pLTR-dS643A-HA protein was reduced by 54% when com-
pared with that of the pLTR-dWT-HA molecule. Autophospho-
rylation of the pCEV-dS643A-HA protein was decreased by
37% when compared with that of pCEV-dWT-HA (Fig. 3B).
Autophosphorylation of endogenous PKC-d from parental 32D
cells was not detected since the anti-HA mAb would not recog-
nize endogenous PKC-d. By normalizing protein expression
levels of PKC-dS643A in comparison to those of PKC-dWT in
the various transfectants (see Fig. 2), an 83% reduction in
pLTR-dS643A-HA autophosphorylation and a 65% reduction in
pCEV-dS643A-HA autophosphorylation were observed. These
results strongly suggest that serine 643 of PKC-d is a major
autophosphorylation site, and mutation of this site dramati-
cally reduces autophosphorylation.
Comparison of Tryptic Phosphopeptides Generated from
PKC-dS643A and PKC-dWT by Two-dimensional Phosphopep-
tide Analysis—To confirm that serine 643 is an in vivo phos-
phorylation site, two-dimensional tryptic phosphopeptide anal-
ysis was performed. As shown in Fig. 4A, tryptic digestion of in
vivo labeled PKC-dWT-HA from the TPA-treated transfectant
resulted in the detection of approximately 20 distinct phos-
phopeptides. The phosphopeptide pattern generated from PKC-
dWT-HA is consistent to that generated in a previous study
(30), assuring that this assay is very reproducible. Although
most of PKC-dWT-HA phosphopeptides were also detected
from tryptic digestion of in vivo labeled PKC-dS643A-HA after
TPA treatment of 32D/pLTR-dS643A-HA transfectant, two
phosphopeptides (peptides 5 and 14) were absent from PKC-
dS643A-HA sample. The reduced intensity of peptide 5 in a
mixture experiment, where equal amounts of PKC-dWT-HA
and PKC-dS643A-HA samples were mixed before performing
two-dimensional phosphopeptide analysis, confirmed that pep-
FIG. 3. Autophosphorylation of PKC-dS643A in vitro is dramat-
ically reduced in comparison to PKC-dWT. A, 32D cells and
pLTR-HA transfectants were serum-starved for 2 h, and equal amounts
of cell lysates were immunoprecipitated (IP) with anti-HA antibody.
Washed immunoprecipitates were subjected to an in vitro autophospho-
rylation assay (see “Experimental Procedures”). Radiolabeled proteins
were resolved by SDS-PAGE and autoradiographed. B, the experiment
was performed in a similar manner to that in A except that the trans-
fectants generated with the pCEV-HA vector were utilized for the
autophosphorylation assay.
FIG. 4. Two-dimensional phosphopeptide analysis of PKC-
dS643A. The radiolabeled PKC-dWT-HA and PKC-dS643A-HA proteins
from TPA-stimulated transfectants were immunoprecipitated with an-
ti-HA, excised after SDS-PAGE, and subjected to phosphopeptide anal-
ysis as described under “Experimental Procedures.” The directions for
electrophoresis and chromatography are marked by long arrows. The
individual phosphopeptides are designated by numbers. After trypsin
digestion, 2000 cpm from each sample were subjected to two-dimen-
sional phosphopeptide analysis (A and B). The mixture in C was gen-
erated by including 1000 cpm of the sample in A plus 1000 cpm of the
sample in B. The points of origin in each panel are marked by arrows.
Two missing phosphopeptides (5 and 14) in PKC-dS643A-HA (B) are
also marked by arrows.
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tide 5 was missing in PKC-dS643A-HA (compare peptide 5 in
Fig. 4, A and C). Since the PKC-dWT-HA sample migrated
slightly slower than the others in chromatography, only a tail
of peptide 14 can be observed (Fig. 4A). This peptide was not
detected in PKC-dS643A-HA sample (Fig. 4B). Therefore,
whether the intensity of peptide 14 detected in the mixture
experiment was reduced (Fig. 4C) is difficult to judge. In addi-
tion, the intensity of peptide 11 was greatly reduced in the
PKC-dS643A-HA sample when compared with PKC-dWT-HA,
and intermediate intensity was observed in the mixture exper-
iment (Fig. 4C). On the other hand, phosphopeptide 19 may be
absent in PKC-dWT-HA. Taken together, the results of two-
dimensional phosphopeptide analysis clearly indicate that the
absence or reduction in intensity of phosphopeptides 5, 14, and
11 may account for the reduced autophosphorylation of PKC-
dS643A in vitro (see Fig. 3).
Enzymatic Activity of PKC-dS643A Mutant Is Greatly De-
creased in Comparison to That of PKC-dWT—The enzymatic
activity of PKC-dS643A expressed in pLTR-HA system was
measured utilizing two separate procedures. In the first assay,
the activities were measured utilizing anti-HA immunoprecipi-
tates as the kinase sources. This method has been recently
used in other PKC studies to measure PKC activity (8, 31). As
shown in Table I, the immunoprecipitates derived from pLTR-
dWT-HA and pLTR-dS643A-HA mutant transfectants dis-
played similar nonspecific catalytic activities when they were
incubated with the PKC-d pseudosubstrate region-derived pep-
tide in the absence of TPA and phosphatidylserine, two impor-
tant cofactors required for specific PKC activation in vitro.
However, the specific PKC-d catalytic activity of pLTR-
dS643A-HA mutant was reduced by 54% when compared with
that of pLTR-dWT-HA protein.
In another PKC activity assay, DE52 ion exchange chroma-
tography was utilized to enrich PKC-d proteins before perform-
ing the kinase assay (6, 30). pLTR-dWT-HA overexpression
resulted in a 14-fold increase in the enzymatic activity com-
pared with that of endogenous PKC-d (Table II). The increased
activity observed in the pLTR-dWT-HA transfectant correlated
with the levels of overexpressed PKC-d protein (data not
shown). Expression of pLTR-dS643A-HA reduced its specific
catalytic activity by 39% compared with that of pLTR-dWT-HA.
By normalizing the protein expression level of pLTR-
dS643A-HA in comparison to that of pLTR-dWT-HA, a 78–84%
reduction in pLTR-dS643A-HA enzymatic activity was calcu-
lated from the results of these two assays (see Fig. 2). In
summary, these results indicate that PKC-d serine 643 is not
only important for autophosphorylation but also for transphos-
phorylation of its in vitro substrate.
The PKC-dS643A Mutant Protein Is Not Thermal Labile—
Recent work on the PKC-aT638A mutant suggested that mu-
tation of threonine 638 rendered the enzyme very sensitive to
heat treatment (23). Thus, we were interested in determining
whether there were any changes in the heat sensitivity of
PKC-dS643A mutant in comparison to PKC-dWT. As shown in
Fig. 5, pLTR-dWT-HA, pLTR-dS643A-HA, and endogenous
PKC activities remained very stable even after a 30-min period
of preincubation at 25 °C. Surprisingly, both pLTR-dWT-HA
and pLTR-dS643A-HA mutant activities were slightly in-
creased after the preincubation period. This result suggests
that phosphorylation of PKC-d on serine 643 does not affect the
heat stability of the enzyme, even though the enzymatic activ-
ity and autophosphorylation of PKC-dS643A are greatly re-
duced in comparison to PKC-dWT.
Localization, Translocation, and Tyrosine Phosphorylation of
PKC-d Are Not Altered When Serine 643 Autophosphorylation
Is Abolished—PKC-d normally resides in the cytosol (S100) of
the cell. In response to stimulation by TPA, a portion translo-
cates to the membrane fraction (P100) (13). Our previous data
demonstrated that PKC-d was tyrosine-phosphorylated in vivo
in response to TPA stimulation, and tyrosine-phosphorylated
PKC-d could be detected only in the membrane fraction (6, 10,
13, 30). Thus, we investigated whether mutation of serine 643
would affect localization, translocation, or tyrosine phosphoryl-
ation of the enzyme. As shown in Fig. 6A, the pLTR-
dS643A-HA mutant as well as pLTR-dWT-HA proteins resided
in the cytosol in resting cells after cell fractionation and immu-
noprecipitation with anti-HA mAb followed by anti-PKC-d im-
munoblot analysis. Stimulation with TPA for 10 min caused
translocation of a similar portion of both pLTR-dWT-HA and
pLTR-dS643A-HA mutant proteins to the membrane fraction
(Fig. 6A, lanes 4 and 6). Reblotting the membrane with anti-
Tyr(P) mAb showed that both pLTR-dWT-HA and pLTR-
dS643A-HA mutant proteins were tyrosine-phosphorylated in
TPA-stimulated samples (Fig. 6B, lanes 4 and 6). As previously
demonstrated (6, 13), tyrosine phosphorylation was observed
only in the membrane fraction. Taken together, the results
indicate that autophosphorylation of PKC-d on serine 643 does
not affect localization, translocation, or tyrosine phosphoryla-
tion of the enzyme.
TPA-induced Monocytic Differentiation of 32D Cells Medi-
TABLE I
The PKC-dS643A mutant protein expressed in 32D cells possesses
reduced enzymatic activity as measured by utilizing anti-HA
immunoprecipitates as PKC-d kinase sources
The method for measuring PKC-d activity by using anti-HA immu-
noprecipitates as PKC-d sources was described under “Experimental
Procedures.” Only one sample from each lysate was utilized for anti-HA
immunoprecipitation and the subsequent activity assay. Thus, no
standard deviation was available. PKC-d specific activity was obtained
by subtracting nonspecific activity from total catalytic activity. The
activity is presented as cpm.
Cell lines Total catalyticactivity
Nonspecific
activity PKC-d activity
32D/pLTR-dWT-HA 1,401,383 246,742 1,154,641
32D/pLTR-dS643A-HA 747,810 214,401 533,409 (54%)a
a The % inhibition of enzymatic activity was determined by subtract-
ing the PKC-d activity of the pLTR-dS643A-HA transfectant from the
pLTR-dWT-HA transfectant and dividing the difference by the activity
of the pLTR-dWT-HA transfectant.
TABLE II
The PKC-dS643A mutant protein expressed in 32D cells possesses reduced enzymatic activity as measured by utilizing DE52 column eluates as
PKC-d kinase sources
The method for PKC enrichment by DE52 ion exchange chromatography and the subsequent activity assay has been described previously (6, 30).
PKC-d specific activity was obtained by subtracting nonspecific activity from total catalytic activity. The results represent the mean value of three
individual samples. The activity is presented as cpm.
Eluates of DE52 column Total catalyticactivity
Nonspecific
activity PKC-d activity
32D 14,060 6 503 6,438 6 432 7,622
32D/pLTR-dWT-HA 130,123 6 8,326 20,051 6 264 110,072
32D/pLTR-dS643A-HA 79,106 6 2,786 11,708 6 332 67,398 (39%)a
a The % inhibition of enzymatic activity was determined by subtracting the PKC-d activity of the pLTR-dS643A-HA transfectant from the
pLTR-dWT-HA transfectant and dividing the difference by the activity of the pLTR-dWT-HA transfectant.
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ated by the PKC-dS643A Mutant Transfectant in Comparison to
the PKC-dWT Transfectant Is Impaired—TPA treatment of
32D cells overexpressing PKC-dWT was able to mediate mono-
cytic differentiation, as judged by changes in morphology, cell
adhesion, nonspecific esterase staining, and cell surface differ-
entiation marker expression (5, 6). Since mutation of PKC-d on
serine 643 reduced its autophosphorylation and its enzymatic
activity, we tested whether PKC-d-mediated monocytic differ-
entiation would be affected. Treatment of the pLTR-
dS643A-HA mutant transfectant with TPA overnight resulted
in reduced cell adhesion and less morphological changes indic-
ative of the macrophage phenotype as analyzed by Wright-
Giemsa staining when compared with the pLTR-dWT-HA
transfectant (data not shown). Flow cytometric analysis was
utilized to detect cell surface differentiation marker expression.
As seen in Fig. 7, stimulation of pLTR-dWT-HA transfectant
with TPA overnight resulted in increased expression of Mac-1
(Fig. 7A) and FcgII/IIIR (Fig. 7B). TPA treatment of the pLTR-
dS643A-HA mutant transfectant resulted in reduced increases
in marker expression in comparison to the pLTR-dWT-HA
transfectant (Fig. 7, A and B). However, the TPA-induced in-
crease in marker expression observed for the pLTR-dS643A-HA
mutant transfectant was still greater than that for the parental
32D cells, indicating that the remaining kinase activity pro-
vided by the pLTR-dS643A-HA mutant was able to partially
mediate the differentiation process. These results suggest that
serine autophosphorylation on amino acid 643 plays an impor-
tant role in PKC-d-mediated monocytic differentiation of 32D
myeloid progenitor cells.
DISCUSSION
In the present study, we have demonstrated that serine 643
of PKC-d is a major autophosphorylation site in vitro and
autophosphorylation of PKC-d on this site is required for its full
enzymatic activity. TPA-induced monocytic differentiation of
32D cells overexpressing PKC-dS643A is reduced in compari-
son to the PKC-dWT transfectant, suggesting that the mutant
protein is less efficient at activating key substrate(s) which
affect the differentiation process. The effects of site-directed
mutagenesis of PKC-a and PKC-bI at similarly conserved sites
were recently reported (23, 29). Although no in vitro autophos-
phorylation data were presented in either study, transphospho-
rylation of the histone substrate in vitro by PKC-aT638A mu-
tant was reduced by 26% (23). In contrast, the PKC-bIT642A
mutant completely abolished in vivo phosphorylation and en-
zymatic activity (29). Whether mutagenesis of PKC-bI affected
the general conformation of the protein remains to be deter-
mined. This was suggested by the inability to label in vivo the
PKC-bIT642A mutant protein with [32P]orthophosphate. Al-
though an ATP binding mutant of PKC-d (PKC-dK376R) gen-
erated in our laboratory was completely devoid of autophospho-
rylation capacity (6), it could still be labeled in vivo by
[32P]orthophosphate.2 Two-dimensional phosphopeptide map-
ping of the PKC-dK376R mutant revealed that at least two
autophosphorylation sites were absent when compared with
PKC-dWT, indicating that other sites in addition to serine 643
2 W. Li, unpublished observations.
FIG. 5. PKC-dS643A mutant protein is thermal stable. Equal
amounts of the various cell lysates were enriched for PKC-d using DE52
chromatography. Eluates were incubated in a 25 °C water bath for
various periods and assayed for PKC-d activity using the PKC-d
pseudosubstrate region-derived peptide as a substrate (6). The PKC-d
specific activity was calculated by subtracting the nonspecific catalytic
activity from the total catalytic activity as described in Table II. The
variation between the three samples utilized to calculate the mean
value of the total catalytic and nonspecific activity was less than 5% of
the mean value. The lines with diamonds, circles, and squares represent
PKC-specific activity from 32D/pLTR-dWT-HA, 32D/pLTR-dS643A-HA,
and the parental 32D line, respectively.
FIG. 6. Localization, translocation, and tyrosine phosphoryla-
tion of the PKC-dS643A mutant protein are not altered in com-
parison to PKC-dWT. A, 32D cells and the transfectants were serum-
starved for 2 h and stimulated with TPA for 10 min. The membrane
fraction (P100) was separated from cytosolic fraction (S100) according
to previously established methods (13). Equal amounts of proteins were
immunoprecipitated (IP) with anti-HA mAb and resolved by SDS-
PAGE. Transferred proteins were immunoblotted (Blot) with anti-
PKC-d serum. B, the same Immobilon membrane utilized in A was
reblotted (Blot) with anti-Tyr(P) mAb.
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must contribute to PKC-d autophosphorylation.2 Moreover, the
present results provide evidence that autophosphorylation of
the PKC-dS643A mutant is not completely abolished (see Fig.
3). PKC-dS643A mutant could be labeled in vivo to a similar
extent as PKC-dWT (see Fig. 4). Based on recent mapping and
site-directed mutagenesis results involving PKC-a at serine
657 (24) and PKC-bII at serine 660 (20), we predict that the
corresponding serine 662 of PKC-d may be an additional auto-
phosphorylation site.
Generation of a serine 643 to alanine mutant of PKC-d did
not affect the translocation of PKC-d from the cytosol to the
membrane in response to TPA stimulation, nor did it affect its
tyrosine phosphorylation in vivo. These data indicate that site-
directed mutagenesis did not alter the general conformation of
the molecule. This is also suggested by the similar two-dimen-
sional phosphopeptide pattern observed for both PKC-dWT and
PKC-dS643A (see Fig. 4, A and B). Translocation of PKC from
the cytosol to the membrane is dependent on the binding of
phorbol ester or endogenously produced diacylglycerol to the
regulatory domain of PKC (1). Tyrosine phosphorylation of
PKC-d has also been mapped at the N terminus of PKC-d (30).
Therefore, it was not surprising that mutation of serine 643 did
not affect these events since this mutation resides in the C
terminus of the molecule. Although phosphorylation has been
implicated to be important for PKC localization, expression of
PKC-dS643A did not alter the localization of the molecule. This
can be best explained by the finding that in vitro autophospho-
rylation was diminished by only 65–83% in the mutant (see
Fig. 3). Thus, alternative autophosphorylation sites may com-
pensate and allow the mutant protein to normally regulate
localization through phosphorylation and dephosphorylation
dynamics.
In summary, our results demonstrate that serine 643 is a
major autophosphorylation site of PKC-d. Autophosphorylation
of PKC-d on this site is indispensable for its full enzymatic
activity but is not required or sufficient for determining the
localization, translocation, or tyrosine phosphorylation of
PKC-d. Mapping the remaining autophosphorylation site(s)
within PKC-d should make it feasible to determine the com-
plete role of autophosphorylation and its effects on the various
aspects of PKC-d function.
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FIG. 7. Monocytic differentiation mediated by PKC-dS643A
mutant expression in 32D cells in response to TPA treatment is
impaired. Cells were either untreated (zzz) or exposed to TPA (O)
overnight and subjected to flow cytometry after incubation with anti-
Mac-1 (A) or anti-FcgII/IIIR (B) antibodies conjugated with fluorescein
isothiocyanate. The x axis represents the mean fluorescence intensity of
fluorescein isothiocyanate and y axis represents relative cell number.
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